You are missing some Flash content that should appear here! Perhaps your browser cannot display it, or maybe it did not initialise correctly.
Home › News & events

News & events

Innate Pharma initiates collaboration with Celgene to evaluate the clinical potential of REVLIMID® combined with anti-kir antibody IPH 2101 in patients with multiple myeloma

November 18, 2009
  • Initiation of a Phase II trial in multiple myeloma evaluating the combination of IPH 2101 - a fully human anti-KIR monoclonal antibody stimulating NK cells' anti-tumoral activity, with Celgene’s REVLIMID®
  • Growing body of evidence in hematological malignancies supports REVLIMID® enhanced NK-mediated cytotoxicity and its potential synergy with IPH 2101’s mechanism of action

Innate Pharma SA announces its turnover for the third quarter of 2009 and updates on its cash situation

November 6, 2009
  • Turnover for the first nine months of 2009 amounted to 2.8 million euros
  • As at September 30, 2009, cash, cash equivalents and current financial instruments amounted 30.5 million euros
     

Innate Pharma moves forward anti-KIR monoclonal antibody IPH 2101 development with study extension in acute myeloid leukemia

November 2, 2009
  • Other Phase I/II or IIa trials are planned with this drug candidate
  • In the context of the French new "anti-cancer plan" announcement, IPH 2101 was presented to government officials

Innate Pharma reports Phase II clinical data with IPH 1101 in oncology

September 21, 2009
  • Encouraging interim efficacy data in non-Hodgkin’s lymphoma (“NHL”) reported at the ESMO meeting in Berlin; complete response rate above current standard of care for the first set of patients
  • Enrolment of patients in the initial Phase I/II and Phase IIa program with IPH 1101 started in 2006 completed; final data to open window for partnering discussions

Description of the Company’s authorization to purchase of its own shares adopted during the general shareholders’ meeting on june 23, 2009

September 18, 2009

During the General Shareholders’ Meeting which took place on June 23, 2009, the general meeting of Innate Pharma (the Company - Euronext Paris: FR0010331421 – IPH) has authorized the Executive Board to purchase its own shares through a share repurchase program.

Innate Pharma enters into a liquidity agreement with Natixis Securities

September 18, 2009

Innate Pharma (the Company - Euronext Paris: FR0010331421 – IPH) announces today the signature of a liquidity agreement with NatIxis Securities. The agreement will be effective September 21, 2009, for a period of one year with tacit renewal.
Innate Pharma has allocated 300,000 euros (three hundred thousands) to this contract.